Week in Review: $1.4 Billion in China Life Science Deals and Financings

21:47 EDT 15 Sep 2018 | ChinaBio Today

Deals and Financings

  • Vivo Capital closed its tenth US-China fund, a private equity healthcare fund, at an oversubscribed $635 million, bringing total assets under management to $2.2 billion;
  • Xynomic, a US-China clinical-stage oncology pharma, will complete a reverse merger with NASDAQ-listed Bison Capital that values Xynomic at $450 million;
  • Hua Medicine of Beijing priced its Hong Kong IPO at the low end of the range to raise $110 million at a valuation of $1.1 billion;
  • 111, Inc., a China retail online/offline pharmacy, completed a US IPO raising $100 million at a $1.1 billion market capitalization;
  • Tianjin Tasly Pharma out-licensed US marketing rights for its angina TCM, currently in US Phase III trials, to Arbor Pharma in a $50 million deal;
  • Zai Lab paid $15 million upfront to acquire greater China rights to Novocure's electric fields therapy for cancer;
  • Cadrock Pty of Australia raised $5 million from an unnamed China investor for clinical trials of a triple-antibiotic as a coronary artery disease treatment;
  • Shanghai Pharma signed a MOU with Russian biotech BIOCAD to form JVs that manufacture and develop BIOCAD's biologic/biosimilar drugs for China;

Trials and Approvals

  • Shanghai's CARsgen presented positive early clinical data of a first-in-class CAR-Claudin18.2 T cell trial in patients with pancreatic and gastric cancer;
  • Innovent Biologics of Suzhou announced that China's NMPA has approved an IND application for its anti-CD47 mAb in multiple tumor types;
  • Shanghai's EpimAb Biotherapeutics filed US and China INDs simultaneously for a bispecific antibody that targets EGFR and cMET receptors.

Stock Symbols: (NSDQ: BCAC) (HK: 2552) (NSDQ: YI) (SHA: 600535) (SHA: 601607) (NSDQ: ZLAB) (NSDQ: NVCR)

Share this with colleagues:

Original Article: Week in Review: $1.4 Billion in China Life Science Deals and Financings


More From BioPortfolio on "Week in Review: $1.4 Billion in China Life Science Deals and Financings"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...